Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Gains from Investment Securities (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Gains from Investment Securities for 5 consecutive years, with $59.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 268.63% year-over-year to $59.0 million, compared with a TTM value of $14000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $14000.0, down 97.77% over the prior year.
  • Gains from Investment Securities was $59.0 million for Q4 2025 at Aligos Therapeutics, up from $4.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $59.0 million in Q4 2025 and bottomed at -$61.5 million in Q1 2025.
  • Average Gains from Investment Securities over 5 years is $171625.0, with a median of $26000.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 268.63% in 2025, while the deepest fall reached 323752.63% in 2025.
  • Year by year, Gains from Investment Securities stood at $2.6 million in 2021, then tumbled by 101.04% to -$27000.0 in 2022, then skyrocketed by 188.89% to $24000.0 in 2023, then soared by 66570.83% to $16.0 million in 2024, then soared by 268.63% to $59.0 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ALGS at $59.0 million in Q4 2025, $4.2 million in Q3 2025, and -$1.7 million in Q2 2025.